Aratana Therapeutics to Present GALLIPRANT® (grapiprant tablets) Pivotal Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Jefferies Reiterates Buy on Aratana Therapeutics (PETX) Following US Galliprant Approval
April 1, 2016 8:25 AM EDTJefferies reiterated a Buy rating and $12.00 price target on Aratana Therapeutics (NASDAQ: PETX) following the company's US approval of Galliprant (AT-001). Galliprant is expected to be available to US veterinarians in Q3'16. Jefferies sees this as a lucrative opportunity, given 9.7m dogs... More
